GI Innovation Inc
KOSDAQ:358570
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GI Innovation Inc
Common Shares Outstanding
GI Innovation Inc
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GI Innovation Inc
KOSDAQ:358570
|
Common Shares Outstanding
₩52.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Common Shares Outstanding
₩218.6m
|
CAGR 3-Years
13%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Common Shares Outstanding
₩20.2m
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Common Shares Outstanding
₩18m
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Common Shares Outstanding
₩53.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
4%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Common Shares Outstanding
₩55.1m
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
GI Innovation Inc
Glance View
GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.
See Also
What is GI Innovation Inc's Common Shares Outstanding?
Common Shares Outstanding
52.3m
KRW
Based on the financial report for Dec 31, 2024, GI Innovation Inc's Common Shares Outstanding amounts to 52.3m KRW.
What is GI Innovation Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 3Y
0%
Over the last year, the Common Shares Outstanding growth was -1%.
